TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07488923: A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)

Sponsor: Moonlight Bio, Inc · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 110 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$7,445,592

Rescue Site Savings

+$4,900,896

Unlock Full NCT07488923 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07488923 Rescue Dossier →